Cancer development is driven by the accumulation of alterations affecting the structure and
function of the genome. Whereas genetic changes disrupt the DNA sequence, epigenetic …

Uterine fibroids are benign monoclonal neoplasms of the myometrium, representing the
most common tumors in women worldwide. To date, no long-term or noninvasive treatment …

The majority of breast cancers express the estrogen receptor (ERα) and agents targeting this
pathway represent the main treatment modality. Endocrine therapy has proven successful in …

The histone deacetylase (HDAC) enzymes, a class of epigenetic regulators, are historically
well established as attractive therapeutic targets. During investigation of trends within …

Smoking is a major risk factor for a variety of diseases, including cancer and immune-
mediated inflammatory diseases. Tobacco smoke contains a mixture of chemicals, including …

Simple Summary Next-generation sequencing (NGS) is a powerful tool used in genomics
research. NGS can sequence millions of DNA fragments at once, providing detailed …

The flexibility of the epigenome has generated an enticing argument to explore its reversion
through pharmacological treatments as a strategy to ameliorate disease phenotypes. All …

Epigenetic drug discovery field has evidenced significant advancement in the recent times.
A plethora of small molecule inhibitors have progressed to clinical stage investigations and …

Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver and
has a high fatality rate. Genetic and epigenetic aberrations are commonly observed in HCC …

Effective anticancer immunotherapy treatments constitute a qualitative leap in cancer
management. Nonetheless, not all patients benefit from such therapies because they fail to …